The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5103-5112

  Deris, Zakuan Z ^a,b   Yu, Heidi H ^a   Davis, Kathryn ^a   Soon, Rachel L ^a,c   Jacob, Jovan ^a   Ku, Caron K ^a   Poudyal, Anima ^a   Bergen, Phillip J ^a   Tsuji, Brian T ^c   Bulitta, Jurgen B ^a,c   Forrest, Alan ^c   Paterson, David L ^d   Velkov, Tony ^a   Li, Jian ^a   Nationa, Roger L ^a  

^a MONASH UNIVERSITY   (Australia)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; DORIPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; DRUG HALF LIFE; DRUG POTENTIATION; IN VITRO STUDY; INOCULATION; KLEBSIELLA PNEUMONIAE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STEADY STATE;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DRUG SYNERGISM; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 84866331856     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01064-12     Document Type: Article

References (52)

1. Antoniadou A, et al. 2007. Colistin-resistant isolates of Klebsiella pneumoniaeemerging in intensive care unit patients: first report of a multiclonal cluster. J. Antimicrob. Chemother. 59:786-790. (Pubitemid 47073420)
2. Bergen PJ, et al. 2010. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob. Agents Chemother. 54:3783-3789.
3. Bergen PJ, et al. 2011. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob. Agents Chemother. 55:5134-5142.
4. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1953-1958. (Pubitemid 43807511)
5. Bergen PJ, et al. 2011. Synergistic killing of multidrug-resistant Pseudomonasaeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 55:5685-5695.
6. Bogdanovich T, et al. 2011. Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin. Infect. Dis. 53:373-376.
7. Boucher HW, et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
8. Bratu S, et al. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56:128-132. (Pubitemid 41418346)
9. Bulitta JB, et al. 2010. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob. Agents Chemother. 54:2051-2062.
10. Conejo MC, Rodríguez-Martínez JM, Serrano L, Pascual Á. 2011. Comparative activity of doripenem, ertapenem and imipenem against clinical isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases, plasmid-mediated AmpC-type beta-lactamases or both, associated or not with porin deficiency, abstr. P1182. Twenty-first Eur. Congr. Clin. Microbiol. Infect. Dis. (ECCMID)-27th Int. Congr. Chemother. (ICC), Milan, Italy, 7 to 10 May 2011. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
11. DeRyke CA, Crawford AJ, Uddin N, Wallace MR. 2010. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob. Agents Chemother. 54:4503-4505.
12. Dudhani RV, et al. 2010. Elucidation of the pharmacokinetic/ pharmacodynamic determinant of colistin activity against Pseudomonasaeruginosa in murine thigh and lung infection models. Antimicrob. Agents Chemother. 54:1117-1124.
13. Dudhani RV, Turnidge JD, Nation RL, Li J. 2010. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J. Antimicrob. Chemother. 65:1984-1990.
14. European Committee on Antimicrobial Susceptibility Testing. 5 January 2011. Breakpoint tables for interpretation of MICs and zone diameters, version 1.3. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk-test-documents/ EUCAST-breakpoints-v1.3-pdf.pdf.
15. European Committee on Antimicrobial Susceptibility Testing. 2003. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. Clin. Microbiol. Infect. 9:ix-xv.
16. Farrell A, Clancy C, Press E, Shields RK. 2011. A combination of colistin + doripenem + ertapenem is effective against Klebsiella pneumoniaeproducing carbapenemase (KPC) isolates with high-level colistin (C) and carbapenem (CBM) resistance, abstr. P-252. Infect. Dis. Soc. Am. (IDSA) Annu. Meet., Boston, MA, 20 to 23 October 2011.
17. Garonzik SM, et al. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284-3294.
18. Gootz TD. 2006. The forgotten Gram-negative bacilli: what genetic determinants are telling us about the spread of antibiotic resistance. Biochem. Pharmacol. 71:1073-1084.
19. Hartzell JD, et al. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48:1724-1728.
20. Hawley JS, Murray CK, Jorgensen JH. 2008. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother. 52:351-352.
21. Ho J, Tambyah PA, Paterson DL. 2010. Multiresistant Gram-negative infections: a global perspective. Curr. Opin. Infect. Dis. 23:546-553.
22. Infectious Diseases Society of America. 2011. Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 52: S397-S428.
23. Jernigan MG, Press EG, Nguyen MH, Clancy CJ, Shields RK. 19 March 2012. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.Antimicrob. Agents Chemother. doi:10.1128/AAC.06364-11.
24. Karabinis A, et al. 2004. Colistin for Klebsiella pneumoniae-associated sepsis. Clin. Infect. Dis. 38:e7-e9. doi:10.1086/380461.
25. Kethireddy S, et al. 2007. In vivo pharmacodynamics of colistin against Pseudomonas aeruginosa in thighs of neutropenic mice, abstr. A-4, p 1. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
26. Kontopoulou K, et al. 2010. Hospital outbreak caused by Klebsiella pneumoniaeproducing KPC-2 β-lactamase resistant to colistin. J. Hosp. Infect. 76:70-73.
27. Kumarasamy KK, et al. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10:597-602.
28. Kwon J-A, et al. 2010. Predictors of acute kidney injury associated with intravenous colistin treatment. Int. J. Antimicrob. Agents 35:473-477.
29. Li J, et al. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob. Agents Chemother. 47:1766-1770. (Pubitemid 36548571)
30. Li J, Nation RL. 2006. Old polymyxins are back: is resistance close? Clin. Infect. Dis. 43:663-664. (Pubitemid 44267132)
31. Li J, et al. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
32. Li J, et al. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacterbaumannii. Antimicrob. Agents Chemother. 50:2946-2950.
33. Lim LM, et al. 2010. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30:1279-1291.
34. Mah T-FC, O'Toole GA. 2001. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9:34-39.
35. Marchaim D, et al. 2011. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob. Agents Chemother. 55:593-599.
36. Matthews SJ, Lancaster JW. 2009. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin. Ther. 31:42-63.
37. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. 2011. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J. Antimicrob. Chemother. 66:946-947.
38. Moellering RC. 2010. NDM-1 - a cause for worldwide concern. N. Engl. J. Med. 363:2377-2379.
39. Nandy P, Samtani MN, Lin R. 2010. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob. Agents Chemother. 54:2354-2359.
40. Nation RL, Li J. 2009. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22:535-543.
41. Pankey GA, Ashcraft DS. 2011. Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 70:561-564.
42. Pillai SK, Moellering RC, Jr, Eliopoulos GM. 2005. Antimicrobial combinations, p 365-424. In Lorian V (ed), Antibiotics in laboratory medicine, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
43. Plachouras D, et al. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob. Agents Chemother. 53:3430-3436.
44. Poudyal A, et al. 2008. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J. Antimicrob. Chemother. 62: 1311-1318.
45. Siegel JD, Rhinehart E, Jackson M, Chiarello L, Healthcare Infection Control Practices Advisory Committee. 2006. Management of multidrug-resistant organisms in healthcare settings, 2006, p 5. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/hicpac/pdf/MDRO/MDROGuideline2006. pdf.
46. Souli M, et al. 2009. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-β- lactamase-producing Klebsiella pneumoniae isolates? Antimicrob. Agents Chemother. 53:2133-2135.
47. Stressmann FA, et al. 2011. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J. Cyst. Fibros. 10:357-365.
48. Tóth Á, et al. 2010. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur. J. Clin. Microbiol. Infect. Dis. 29:765-769.
49. Urban C, Mariano N, Rahal JJ. 2010. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiellapneumoniae, and Escherichia coli. Antimicrob. Agents Chemother. 54:2732-2734.
50. Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM. 2009. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn. Microbiol. Infect. Dis. 63:409-414.
51. Yau W, et al. 2009. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J. Infect. 58:138-144.
52. Ziv G, Wanner M, Nicolet J. 1980. Clinical pharmacology of polymyxin B, colistin and colistimethate in young dairy calves. J. Vet. Pharmacol. Ther. 3:87-94.